These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 10792785)

  • 1. Incidence of P53 and K-ras alterations in ovarian mucinous and serous tumors.
    Morita K; Ono Y; Fukui H; Tomita S; Ueda Y; Terano A; Fujimori T
    Pathol Int; 2000 Mar; 50(3):219-23. PubMed ID: 10792785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary.
    Fujita M; Enomoto T; Inoue M; Tanizawa O; Ozaki M; Rice JM; Nomura T
    Jpn J Cancer Res; 1994 Dec; 85(12):1247-56. PubMed ID: 7852189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. K-ras gene point mutations and p21ras immunostaining in human ovarian tumors.
    Semczuk A; Postawski K; Przadka D; Rozynska K; Wrobel A; Korobowicz E
    Eur J Gynaecol Oncol; 2004; 25(4):484-8. PubMed ID: 15285310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy.
    Jimenez RE; Warshaw AL; Z'graggen K; Hartwig W; Taylor DZ; Compton CC; Fernández-del Castillo C
    Ann Surg; 1999 Oct; 230(4):501-9; discussion 509-11. PubMed ID: 10522720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors.
    Ichikawa Y; Nishida M; Suzuki H; Yoshida S; Tsunoda H; Kubo T; Uchida K; Miwa M
    Cancer Res; 1994 Jan; 54(1):33-5. PubMed ID: 8261457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance.
    Wamunyokoli FW; Bonome T; Lee JY; Feltmate CM; Welch WR; Radonovich M; Pise-Masison C; Brady J; Hao K; Berkowitz RS; Mok S; Birrer MJ
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):690-700. PubMed ID: 16467078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology.
    Mandai M; Konishi I; Kuroda H; Komatsu T; Yamamoto S; Nanbu K; Matsushita K; Fukumoto M; Yamabe H; Mori T
    Hum Pathol; 1998 Jan; 29(1):34-40. PubMed ID: 9445131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary.
    Enomoto T; Weghorst CM; Inoue M; Tanizawa O; Rice JM
    Am J Pathol; 1991 Oct; 139(4):777-85. PubMed ID: 1656759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection and clinical correlations of ras gene mutations in human ovarian tumors.
    Varras MN; Sourvinos G; Diakomanolis E; Koumantakis E; Flouris GA; Lekka-Katsouli J; Michalas S; Spandidos DA
    Oncology; 1999; 56(2):89-96. PubMed ID: 9949292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
    Teneriello MG; Ebina M; Linnoila RI; Henry M; Nash JD; Park RC; Birrer MJ
    Cancer Res; 1993 Jul; 53(13):3103-8. PubMed ID: 8319218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases.
    Cuatrecasas M; Villanueva A; Matias-Guiu X; Prat J
    Cancer; 1997 Apr; 79(8):1581-6. PubMed ID: 9118042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
    Mayr D; Hirschmann A; Löhrs U; Diebold J
    Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu.
    Hakim AA; Barry CP; Barnes HJ; Anderson KE; Petitte J; Whitaker R; Lancaster JM; Wenham RM; Carver DK; Turbov J; Berchuck A; Kopelovich L; Rodriguez GC
    Cancer Prev Res (Phila); 2009 Feb; 2(2):114-21. PubMed ID: 19174584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors.
    Caduff RF; Svoboda-Newman SM; Ferguson AW; Johnston CM; Frank TS
    Am J Surg Pathol; 1999 Mar; 23(3):323-8. PubMed ID: 10078924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
    Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
    Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. k-ras mutation may be an early event in mucinous ovarian tumorigenesis.
    Garrett AP; Lee KR; Colitti CR; Muto MG; Berkowitz RS; Mok SC
    Int J Gynecol Pathol; 2001 Jul; 20(3):244-51. PubMed ID: 11444200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation of K-RAS protooncogene and loss of heterozygosity on 6q27 in serous and mucinous ovarian carcinomas.
    Suzuki M; Saito S; Saga Y; Ohwada M; Sato I
    Cancer Genet Cytogenet; 2000 Apr; 118(2):132-5. PubMed ID: 10748293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer.
    Okuda T; Otsuka J; Sekizawa A; Saito H; Makino R; Kushima M; Farina A; Kuwano Y; Okai T
    Gynecol Oncol; 2003 Mar; 88(3):318-25. PubMed ID: 12648581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 20. Ovarian mucinous tumor with malignant mural nodules: dedifferentiation or collision?
    Desouki MM; Khabele D; Crispens MA; Fadare O
    Int J Gynecol Pathol; 2015 Jan; 34(1):19-24. PubMed ID: 25473748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.